The FDA advisory vote is July 23–24 — 6 days out.The countdown isn't your deadline. Here's why — and what actually is.
On July 23–24, an FDA advisory committee votes on whether seven peptides — including BPC-157 — can be added to the list a compounding pharmacy may legally build from. FDA's own career staff walked in with written recommendations against all seven. So the most likely near-term outcome is no new legal pathway.
What that means for you: the vote is not your deadline, and even a "yes" would not make anything legal for a year-plus. Your real exposure this month is where you source and what you claim — not what the committee decides. This brief is the evidence, the directional call, and the decision playbook — every line linked to its primary source so you can verify it yourself.
What's inside Issue 00
The load-bearing finding most coverage buries — verified against all seven FDA briefing documents, not a rumor.
Where this is actually heading (12–36 months) — the bifurcation call, and the six signals to watch in priority order.
The decision playbook — what to do now regardless of the vote, what changes under each outcome, and what not to do.
The moat you can't see — four places AI plugs into your sourcing and claims exposure, concrete and near-term.
The one-page action checklist — and a primary-source link on every claim.
"An operator who staffs up, stocks up, or rewrites the patient pitch around an expected 'yes' is betting against FDA's own chemists."
★ Founding rate — locked for life
$49$99
per year · about $0.94 a week · one good call out of fifty pays for the year
Secure checkout via Stripe · annual · founding price never rises for founding members
This brief synthesizes public FDA filings, the Federal Register, and published legal analysis. It is information, not legal advice; consult counsel licensed in your state before acting.